Archive for January, 2013

New Long Acting Insulin From Novo Nordisk Approved by EU

Novo nordisk logo

The European Commission have granted Novo Nordisk approval for the long acting insulin Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) across all European Union member states for diabetic patients. The new treatments from Novo Nordisk can reduce diabetic complications and allow fewer injections according to the company, which if true might be sensational news [...]